We are now in a data, compute and algorithm rich world, and still the discovery of new drugs is a major global challenge for many chronic diseases. It is clear though, that significant progress can be made, as evidenced by the rapid development and approval of novel small molecule and biological therapies for Covid-19. The talk will detail the need for radical increases in productivity and speed, industrialisation and automation, and how machine learning approaches can address both target discovery and validation, and lead discovery and optimisation. Other opportunities for machine learning to make impact addressing drug combinations and acquired resistance in cancer and infectious disease are detailed.
Opportunities for Machine Learning in Drug Discovery
March, 22 at 1 pm (BRT)
Speaker:
Dr. John P. Overington
VP, Scientist - Exscientia
Visiting Professor - University College London, UK
Moderator:
Dr. Mírian Akemi Hayashi
Associate Professor - EPM/UNIFESP
Link para inscrição, clique aqui
Access with full name in the field "não tenho uma conta"